{"entity":{"id":"nct03644056","kind":"trial","name":"Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors","aka":[],"tldr":"A phase 1 trial of IMC-001 run by ImmuneOncia Therapeutics Inc., completed.","summary":"Dose-escalation Study of IMC-001 in Subject With Metastatic or Locally-advanced Solid Tumors is a phase 1 interventional study registered as NCT03644056 by ImmuneOncia Therapeutics Inc., with 15 participants enrolled, started 2018-03-22. Conditions recorded: Solid Tumor, Metastasis and Locally Advanced. Interventions recorded: IMC-001.","status":"completed","asOf":"2026-11-03","links":[{"label":"ClinicalTrials.gov NCT03644056","url":"https://clinicaltrials.gov/study/NCT03644056"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["metastatic-cancer"],"sections":[],"technologies":[],"targets":[],"drugs":["imc-001"],"companies":["immuneoncia-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT03644056","phase":"1","setting":"A Phase 1, Open-label, Multiple-ascending Dose Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of IMC-001 in Subjects With Metastatic or Locally-advanced Solid Tumors","sponsor":"ImmuneOncia Therapeutics Inc.","enrolled":15,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct03644056/","neighbours":{"cancer":[{"id":"metastatic-cancer","kind":"cancer","name":"Metastatic cancer (cancer that has spread)","route":"/cancers/metastatic-cancer/"}],"drug":[{"id":"imc-001","kind":"drug","name":"IMC-001","route":"/drugs/imc-001/"}],"company":[{"id":"immuneoncia-therapeutics","kind":"company","name":"ImmuneOncia Therapeutics","route":"/companies/immuneoncia-therapeutics/"}]}}